GlassScriptPhysician profile
Muhammad Bostaji
NPI 1609875046
$10,861.53
in general payments reported to CMS, 2019-2025
25 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,982 · 2020: $981 · 2021: $2,271 · 2022: $2,344 · 2023: $1,114 · 2024: $1,052 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,441 · Food and Beverage: $765 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,440.83 |
| Food and Beverage | $765.44 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $2,461.67 | 2019-2025 | Spiration Valve System |
| Steris Corporation | $1,683.87 | 2022 | |
| Glaxosmithkline, LLC. | $1,613.09 | 2019-2023 | Nucala, Trelegy Ellipta |
| Pinnacle Biologics, INC | $1,235.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $1,048.15 | 2019-2023 | Fasenra |
| Noah Medical Corporation | $999.88 | 2023-2024 | Galaxy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.83 | 2019-2022 | |
| Genzyme Corporation | $303.06 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $208.34 | 2019-2023 | Dupixent |
| Intuitive Surgical, INC. | $134.74 | 2025 | |
| Mylan Specialty L.P. | $112.66 | 2020-2021 | |
| Philips North America LLC | $111.46 | 2019-2024 | (Ak6) Vest Therapy |
| Teva Pharmaceuticals USA, INC. | $85.66 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2023 | |
| Tempus Ai, INC | $70.51 | 2024-2025 | Xt Cdx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $27.98 | 2022 | |
| Pharmacosmos Therapeutics INC. | $27.74 | 2024 | Monoferric |
| Genmab U.S., INC. | $26.11 | 2025 | Tivdak |
| Mallinckrodt Hospital Products INC. | $25.07 | 2023 | Acthar |
| Aadi Bioscience, INC. | $21.77 | 2024 | Fyarro |
| Merck Sharp & Dohme LLC | $18.54 | 2025 | Keytruda |
| Sunovion Pharmaceuticals INC. | $18.07 | 2020 | |
| Abbvie INC. | $17.93 | 2024 | |
| Jazz Pharmaceuticals INC. | $17.85 | 2025 | |
| Circassia INC. | $17.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bostaji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.